WAVE - World Association for Vaccine Education Home About Us Contact Us Legal & Privacy
Specific Vaccines
Flu (influenza)
Flu (influenza) Information
View evidence of Flu (influenza) Vaccine Risk
View evidence of Flu (influenza) Vaccine Ineffectiveness

Flu (influenza) Vaccines

Afluria flu (influenza) vaccine
Manufacturer CSL Biotherapies
Microorganism influenza virus
Licensed 09/28/2007
Recommendations One intramuscular injection
Ingredients Beta-propiolactone, Neomycin, Polymyxin B, Sucrose, Thimerosal, Mercury, Sodium phosphate-monobasic, Chick embryo cells, Potassium chloride, Neomycin sulphate, Calcium chloride, Sodium deoxycholate, Sodium phosphate- dibasic anhydrous, Potassium phosphate- monobasic.
Product Descriptions

Package Insert

Agriflu trivalent inactivated influenza virus vaccine
Manufacturer Novartis Vaccines and Diagnostics, Inc.
Microorganism influenza virus subtypes A and type B, A/Brisbane/59/2007, IVR-148 (H1N1); A/Uruguay/716/2007, NYMC X-175C (H3N2) (an A/Brisbane/10/2007-like virus); and B/Brisbane/60/2008
Licensed Nov 2009
Recommendations one intramuscular injection in persons 18 years of age and older
Ingredients Formaldehyde, Polysorbate 80, Kanamycin (antibiotic), Egg protein, Neomycin sulphate, Virus: Influenza, cetyltrimethylammonium bromide (CTAB).
Product Descriptions

Package Insert (FDA)

Immune system disorders:
Hypersensitivity reactions (including throat and/or mouth edema, anaphylaxis, and anaphylactic shock) Musculoskeletal and connective tissue disorders: Arthralgia, myalgia.

Nervous system disorders:
Headache, syncope shortly after vaccination, dizziness, neuralgia, paraesthesia, convulsion, myelitis (including encephalomyelitis and transverse myelitis), neuropathy (including neuritis and brachial plexus neuropathy), paralysis

Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.

Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.

Headache, syncope shortly after vaccination, dizziness, neuralgia, paraesthesia, convulsion, myelitis (including encephalomyelitis and transverse myelitis), neuropathy (including neuritis and brachial plexus neuropathy), paralysis

Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.

Guillain-Barré Syndrome

Nervous system disorders:
Headache, syncope shortly after vaccination, dizziness, neuralgia, paraesthesia, convulsion, myelitis (including encephalomyelitis and transverse myelitis), neuropathy (including neuritis and brachial plexus neuropathy), paralysis

Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.

Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.

Headache, syncope shortly after vaccination, dizziness, neuralgia, paraesthesia, convulsion, myelitis (including encephalomyelitis and transverse myelitis), neuropathy (including neuritis and brachial plexus neuropathy), paralysis

Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.

Guillain-Barré Syndrome

Nervous system disorders:
Headache, syncope shortly after vaccination, dizziness, neuralgia, paraesthesia, convulsion, myelitis (including encephalomyelitis and transverse myelitis), neuropathy (including neuritis and brachial plexus neuropathy), paralysis

Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.

Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.

Headache, syncope shortly after vaccination, dizziness, neuralgia, paraesthesia, convulsion, myelitis (including encephalomyelitis and transverse myelitis), neuropathy (including neuritis and brachial plexus neuropathy), paralysis

Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.

Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give AGRIFLU should be based on careful consideration of the potential benefits and risks.

Carcinogenesis, Mutagenesis, Impairment of Fertility
AGRIFLU has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility.

AGRIFLU has not been evaluated for carcinogenic or mutagenic potential, or for impairment of male fertility.


Arepanrix H1N1 AS03-Adjuvanted H1N1 Pandemic Influenza Vaccine
Manufacturer GlaxoSmithKline
Microorganism A/California/7/2009 (H1N1)v-like strain (X-179A) 3.75µg HA
Licensed 10/13/2009 (Canada)
Recommendations Adults aged 18-60 years: The need for a second dose is currently unknown (If a second dose is needed, it should be given after an interval of at least three weeks) Children and adolescents aged 10-17 years: No clinical data are available for any influenza vaccines with AS03 in this age group. Consideration may be given to dosing in accordance with recommendations for adults. Children aged 3-9 years: Based on limited clinical data available for AS03-adjuvanted H5N1 vaccine containing 3.75 ìg HA derived from A/Vietnam/1194/2004 in this age group, 0.25mL of vaccine (i.e. half of the adult dose) at an elected date and a second dose administered at least three weeks later may be considered sufficient. See section Pharmacodynamics. Children aged from 6-35 months: No clinical data are available for influenza vaccines with AS03 in this age group. Consideration may be given to dosing in accordance with the recommendation in children aged 3-9 years. Children aged less than 6 months: Vaccination is not currently recommended in this age group.
Ingredients Formaldehyde, Polysorbate 80, Squalene, Thimerosal, Mercury, Egg protein, Sodium deoxycholate, DL-á-tocopherol.
Product Descriptions

Package insert

Manufacurer leaflet (GSK)



Begrivac Influenza vaccine (split virion, inactivated)
Manufacturer Wyeth
Microorganism Influenza virus
Licensed 08/13/1998
Recommendations From children 6 months and older, one i.m. injection, size of dose smaller for 6-36 months, booster dose recommended for children who have not previously been vaccinated
Ingredients Formaldehyde, Polymyxin B, Polysorbate 80, Sucrose, Sodium chloride, Potassium dihydrogen phosphate, Disodium phosphate dehydrate, Potassium chloride, Egg protein, Virus: Influenza virus antigens, Magnesium chloride hexahydrate, Diethylether.
Product Descriptions

http://medguides.medicines.org.uk/displaypage.aspx?t=medicine&i=52
http://emc.medicines.org.uk/emc/industry/default.asp?remoteSearch=Begrivac

http://www.google.com/search?hl=en&safe=off&q=Begrivac%2C+intramuscular
http://www.pei.de/nn_163516/EN/drugs/impfstoffe-am-en/influenza-en/influenza-node-en.html?__nnn=true



Celvapan (swine flu) Pandemic influenza vaccine (H1N1) (whole virion, Vero cell derived, inactivated)
Manufacturer Baxter AG
Microorganism A/California/07/2009 (H1N1) 7.5 micrograms
Licensed 04/03/2009 (EU/1/08/506/001)
Recommendations Adults and elderly - A dose (0.5 ml) of the vaccine will be given. A second dose of the vaccine should be given after an interval of at least three weeks. Children and adolescents aged 6 months to 17 years of age -- If it is considered that you or your child needs to be vaccinated, you/he/she may receive one dose of 0.5 ml vaccine and a second dose of 0.5 ml at least three weeks later. Children aged less than 6 months -- Vaccination is not currently recommended in this age group.
Ingredients Formaldehyde, Polysorbate 80, Sucrose, Sodium chloride, Trometamol, Benzonase, propagated in Vero cells .
Product Descriptions

Package Insert

Enzira Influenza vaccine (split virion, inactivated)
Manufacturer CSL
Microorganism Influenza
Licensed 04/19/2005
Recommendations Adults and children from 36 months, children from 6 to 36 months at a reduced dosage, second dose should be given for children that are previously unvaccinated
Ingredients Sodium chloride, Potassium dihydrogen phosphate, Potassium chloride, Sodium dihydrogen phosphate dehydrate, Egg protein, Calcium chloride, Virus: Influenza, Anhydrous disodium phosphate.
Product Descriptions

http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=16589

Fluad® Influenza vaccine
Manufacturer Chiron
Microorganism Infleunza virus
Licensed (EU)
Recommendations
Ingredients Squalene, MF59.
Product Descriptions



Fluarix® Influenza Virus Vaccine
Manufacturer GlaxoSmithKline
Microorganism The Influenza virus.
Licensed 08/31/2005
Recommendations Not for use in children. Single dose for adults
Ingredients Formaldehyde, Gentamicin Sulfate, Latex, Polysorbate 80, Thimerosal, Ovalbumin (egg), Egg protein, Influenza A virus hemagglutinin, Influenza B virus hemagglutinin, Octoxynol-10 (or 9), alpha-tocopheryl, Hydrogen succinate, Hydrocortisone, Sodium deoxycholate.
Product Descriptions

Prescribing Information

Safety Data Sheet

http://www.fda.gov/cber/efoi/approve.htm



FluLaval Influenza Virus Vaccine
Manufacturer GlaxoSmithKline
Microorganism Influenza strains A/New Caledonia/20/99 (H1N1), 15 mcg; A/Wisconsin/67/2005 (H3N2), 15 mcg; B/Malaysia/2506/2004
Licensed 10/05/2006
Recommendations Age 18 or older, single injection.
Ingredients Formaldehyde, Thimerosal, Mercury, Egg protein, Influenza A virus hemagglutinin, Influenza B virus hemagglutinin, Sodium deoxycholate.
Product Descriptions

Prescribing Information

http://www.fda.gov/cber/efoi/approve.htm



FluMist® Live, intranasal influenzae
Manufacturer MedImmune, Wyeth
Microorganism H1N1, H3N2, B/Jilin/20/2003 (B/Shanghai/361/2002-13 like strains of Influenza virus
Licensed 01/05/2007
Recommendations Ages 2-49
Ingredients Gentamicin Sulfate, Monosodium Glutamate (MSG), Sucrose, Potassium phosphate.
Product Descriptions

Prescribing Info

http://www.fda.gov/cber/efoi/approve.htm



Fluvax Inactivated Influenza Vaccine (Split Virion)
Manufacturer CSL Limited
Microorganism Influenza
Licensed
Recommendations One injection yearly, from three months of age with differing strengths according to age.
Ingredients Neomycin, Polymyxin B, Sucrose, Sodium chloride, Sodium phosphate-monobasic, Potassium chloride, Egg protein, Virus: Influenza, Sodium phosphate- dibasic anhydrous, Potassium phosphate- monobasic, Sodium taurodeoxycholate.
Product Descriptions

Package Insert



Fluviral, Fluviral S/F Influenza Virus Vaccine Trivalent, Inactivated Whole-Virion Active Immunizing Agent
Manufacturer Shire (Canada)
Microorganism Influenza virus
Licensed
Recommendations Annually in the fall. Children under 9 years of age require two injections one month apart, the first time they have the vaccine. Differing dosages for different age groups, from 6 months up.
Ingredients Formaldehyde, Thimerosal, Egg protein, Virus: Influenza, Sodium deoxycholate, Triton X-100.
Product Descriptions

Package Insert



Fluvirin® Purified Surface Antigen Vaccine, Trivalent, Types A and B
Manufacturer Chiron Corporation
Microorganism Influenza virus H1N1, H3N2, B/Malaysia/2506/2004 strains
Licensed 07/21/2006
Recommendations Not for use for patients under four years of age: 1 or 2 injections for those 4 to 8 years of age, one injection for those 9 years of age or older.
Ingredients Neomycin, Polymyxin B, Thimerosal, Egg protein, Triton N101, M phosphate- buffered saline.
Product Descriptions

Package Insert

http://www.fda.gov/cber/efoi/approve.htm



Fluzone® influenza virus vaccine trivalent, inactivated
Manufacturer Aventis Pasteur
Microorganism Influenza virus types A and B -- A/New Caledonia/20/99, A/Wyoming/03/2003 (an A/Fujian/411/2002-like, B/Jiangsu/10/2003 (a B/Shanghai/361/2002-like) strains
Licensed 07/10/2006
Recommendations One or two i.m. injections for those 6 months of age or older, (reduced potency for age 6 to 35 months).
Ingredients Formaldehyde, Gelatin, Latex, Thimerosal, Egg protein, Virus: Influenza.
Product Descriptions

University: http://www.vaccinesafety.edu/components-Influenza.htm
http://www.fluzone.com/
http://www.vaccineshoppe.com/us_pdf/fluzone_2005.2006_5097.5098.pdf
http://www.fda.gov/cber/label/inflave071405LB.pdf
http://www.fda.gov/cber/efoi/approve.htm


Focetria (swine flu) Pandemic influenza vaccine (surface antigen, inactivated, adjuvanted)
Manufacturer Novartis Vaccines and Diagnostics
Microorganism A/California/7/2009 (H1N1)v like strain (X-179A181)
Licensed 02 May 2007 (EU/1/07/385/001, EU/1/07/385/002)
Recommendations Adults (18-60 years)and elderly -- One dose of 0.5 ml at an elected date. A second dose of vaccine should preferably be given. There should beafter an interval of at least three weeks between the first and second dose. However, the currently available immunogenicity data obtained at three weeks after administration of Focetria (H1N1) to a limited number of healthy adults aged 18-60 years suggest that a single dose may be sufficient in this age group. Elderly (>60 years): One dose of 0.5 ml at an elected date. A second dose of vaccine should be given after an interval of at least three weeks. See section 5.1. Children and adolescents 6 months to 17 years of age -- One dose of 0.5 ml at an elected date. A second dose of vaccine should be given after an interval of at least three weeks. Children and adolescents aged 9-17 years: One dose of 0.5 ml at an elected date. A second dose of vaccine should preferably be given. There should be an interval of at least three weeks between the first and second dose. Children and adolescents 6 months to 8 years of age: One dose of 0.5 ml at an elected date. A second dose of vaccine should be given after an interval of at least three weeks. Children aged less than 6 months: Vaccination is not currently recommended in this age group.
Ingredients Polysorbate 80, Sorbitol, Squalene, Sodium chloride, Potassium dihydrogen phosphate, Potassium chloride, Sodium citrate, Egg protein, Calcium chloride, Magnesium chloride hexahydrate, MF59, Disodium phosphate dihydrate, Citric acid.
Product Descriptions

Package Insert

Grippol Vaccination for flu prevention three-valence polymer-sub-single liquid
Manufacturer Institute of Immunology
Microorganism Influenza
Licensed
Recommendations children from 6 months, 3 doses with four week intervals ; over 3 years, one dose
Ingredients Virus: Influenza, Superficial glycoproteins (gemagglutinin and neyroamynidasa), Polyoxidonium, Hemagglutinin culture flu viruses of type A(H1N1), A(H3N2).
Product Descriptions

Package Insert



Inflexal, Inflexal S, Inflexal V Influenza vaccine (surface antigen, inactivated, virosomic)
Manufacturer Sanofi Pasteur
Microorganism Influenza
Licensed 03/29/2005
Recommendations from six months, higher dosage for those over 3 years of age
Ingredients Sodium chloride, Egg protein, Virus: Influenza, Disodium dehydrogenate phosphate, Potassium dehydrogenate phosphate, Lecithin.
Product Descriptions

http://www.crucell.com/Products-Inflexal_V
http://www.angelini.it/public/schedepharma/inflexal.htm
http://www.pei.de/nn_163516/EN/drugs/impfstoffe-am-en/influenza-en/influenza-node-en.html?__nnn=true

Influenza A (H1N1) 2009 Monovalent Vaccine Swine Flu, inactivated
Manufacturer Sanofi Pasteur
Microorganism Influenza A/California/07/2009 (H1N1)
Licensed
Recommendations Children: -6 through 35 months of age (0.25 mL dose, intramuscular injection): Two 0.25 mL doses approximately one month apart. (2.2) -36 months through 9 years of age (0.5 mL dose, intramuscular injection): Two 0.5 mL doses approximately one month apart. (2.2) - 10 years of age and older: A single 0.5 mL dose, intramuscular injection. Adults: A single 0.5 mL dose, intramuscular injection.
Ingredients Formaldehyde, Gelatin, Sucrose, Thimerosal, Sodium chloride, Sodium phosphate, Chick embryo cells, Triton X-100, Polyethylene glycol.
Product Descriptions

(Thimerosol ) 25 mcg mercury is present in multi-does vaccine and not single doses.

Manufacturer Package Insert (FDA)

"Neither Fluzone vaccine nor Influenza A (H1N1) 2009 Monovalent Vaccine have been evaluated for carcinogenic or mutagenic potential, or for impairment of fertility. "

"The 1976 swine influenza vaccine was associated with an increased frequency of Guillain-Barré syndrome (GBS)... Neurological disorders temporally associated with influenza vaccination such as encephalopathy, optic neuritis/neuropathy, partial facial paralysis, and brachial plexus neuropathy have been reported. Microscopic polyangitis (vasculitis) has been reported temporally associated with influenza vaccination. "



Influenza A (H1N1) 2009 Monovalent Vaccine Swine Flu inactivated
Manufacturer CSL Limited
Microorganism influenza A/California/7/2009 (H1N1)v-like virus.
Licensed Initial US approval 2007, US License No. 1764
Recommendations Adults 18 years of age and older: A single 0.5 mL intramuscular injection.
Ingredients Beta-propiolactone, Polymyxin B, Sucrose, Thimerosal, Mercury, Sodium chloride, Sodium phosphate-monobasic, Ovalbumin (egg), Chick embryo cells, Neomycin sulphate, Calcium chloride, Sodium phosphate- dibasic anhydrous, Potassium phosphate- monobasic, Sodium taurodeoxycholate, Triton X-100.
Product Descriptions

 Package Insert (FDA)

Influenza A (H1N1) 2009 Monovalent Vaccine, a sterile suspension for intramuscular injection, is supplied in two presentations: 0.5 mL preservative-free, single-dose, pre-filled syringe.
• 5 mL multi-dose vial containing ten doses. Thimerosal, a mercury derivative, is added as a preservative; each 0.5 mL dose contains 24.5 micrograms (mcg) of mercury. 0.5 mL preservative-free, single-dose, pre-filled syringe.

"If GBS has occurred within 6 weeks of previous influenza vaccination, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine should be based on careful consideration of the potential benefits and risks. "

The following adverse reactions also include those identified during postapproval use of AFLURIA outside the US since 1985:
Blood and lymphatic system disorders- Transient thrombocytopenia
Allergic reactions including anaphylactic shock and serum sickness
Nervous system disorders - Neuralgia, paresthesia, and convulsions; encephalopathy, neuritis or neuropathy, transverse myelitis, and GBS
Vascular disorders: Vasculitis with transient renal involvement





Influenza A (H1N1) 2009 Monovalent Vaccine Swine Flu, inactivated
Manufacturer Novartis Vaccines and Diagnostics Ltd.
Microorganism A/California/7/2009 (H1N1)v-like virus
Licensed
Recommendations Children 4 through 9 years of age: Two 0.5-mL intramuscular injections approximately 1 month apart Children 10 through 17 years of age: A single 0.5-mL intramuscular injection Adults 18 years of age and older: A single 0.5-mL intramuscular injection
Ingredients Beta-propiolactone, Neomycin, Polymyxin B, Thimerosal, Mercury, Chick embryo cells, Egg protein, Nonylphenol ethoxylate.
Product Descriptions

Package Insert (FDA)

Guillain-Barr¨¦ Syndrome
If Guillain-Barr¨¦ syndrome has occurred within 6 weeks of receipt of prior influenza vaccine, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine should be based on careful consideration of the potential benefits and risks.
Immune system disorders: Hypersensitivity reactions (including throat and/or mouth edema). In rare cases, hypersensitivity reactions have lead to anaphylactic shock and death. 
Cardiovascular disorders: Vasculitis


Serious allergic reactions, including anaphylactic shock, have been observed in individuals...

Prefilled single dose syringe, 0.5-mL. Thimerosal, a mercury derivative used during manufacture, is removed by subsequent purification steps to a trace amount (1 mcg mercury per 0.5-mL dose)
Multidose vial, 5-mL. Contains thimerosal, a mercury derivative (25 mcg mercury per 0.5-mL dose). Thimerosal is added as preservative.


Serious allergic reactions, including anaphylactic shock, have been observed in individuals...

Prefilled single dose syringe, 0.5-mL. Thimerosal, a mercury derivative used during manufacture, is removed by subsequent purification steps to a trace amount (1 mcg mercury per 0.5-mL dose)
Multidose vial, 5-mL. Contains thimerosal, a mercury derivative (25 mcg mercury per 0.5-mL dose). Thimerosal is added as preservative.


Serious allergic reactions, including anaphylactic shock, have been observed in individuals...

Prefilled single dose syringe, 0.5-mL. Thimerosal, a mercury derivative used during manufacture, is removed by subsequent purification steps to a trace amount (1 mcg mercury per 0.5-mL dose)
Multidose vial, 5-mL. Contains thimerosal, a mercury derivative (25 mcg mercury per 0.5-mL dose). Thimerosal is added as preservative.



Influenza A (H1N1) 2009 Monovalent Vaccine Swine Flu live, intranasal, attenuated
Manufacturer MedImmune, LLC
Microorganism Six internal gene segments responsible for ca, ts, and att phenotypes are derived from a master donor virus (MDV) and pandemic (H1N1) 2009 wild-type virus
Licensed
Recommendations Children (2-9 years) - 2 doses (0.2 mL each, approximately 1 month apart) Children, adolescents and adults (10-49 years) - 1 dose (0.2 mL)
Ingredients Gentamicin Sulfate, Gelatin, Monosodium Glutamate (MSG), Sucrose, Potassium phosphate, Chick embryo cells, Potassium phosphate- monobasic, Arginine.
Product Descriptions

Package Insert (FDA)

Contraindications: Hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or life threatening reactions to previous influenza vaccination.

Guillain-Barré Syndrome
If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal or FluMist should be based on careful consideration of the potential benefits and potential risks. If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal or FluMist should be based on careful consideration of the potential benefits and potential risks

If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal or FluMist should be based on careful consideration of the potential benefits and potential risks

Influenza A (H1N1) 2009 Monovalent Vaccine split-virion, inactivated influenza virus subtype A
Manufacturer ID Biomedical Corporation of Quebec (IDB) (Distributed by GlaxoSmithKline)
Microorganism A/California/7/2009 (H1N1)v-like virus.
Licensed Nov 10, 2009
Recommendations Adults 18 years of age and older: A single 0.5-mL intramuscular injection
Ingredients Formaldehyde, Thimerosal, Mercury, Ovalbumin (egg), Egg protein, Virus: Influenza virus antigens, Sodium deoxycholate.
Product Descriptions

Package Insert (FDA)

*If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give Influenza A (H1N1) 2009 Monovalent Vaccine should be based on careful consideration of the potential benefits and risks. Limitations of Vaccine Effectiveness: Vaccination with Influenza A (H1N1) 2009 Monovalent Vaccine may not protect all susceptible individuals.
Nervous System Disorders: Dizziness, paresthesia, hypoesthesia, hypokinesia, tremor, somnolence, syncope, Guillain-Barré syndrome, convulsions/seizures, facial or cranial nerve paralysis, encephalopathy, limb paralysis.
embryonated hens’ eggs.
formaldehyde



Influvac Influenza vaccine, surface antigen, inactivated
Manufacturer Solvay-Pharma
Microorganism Influenza
Licensed 07/15/2005
Recommendations Adults, elderly, and children over 36 months, single injection.
Ingredients Formaldehyde, Sodium chloride, Potassium dihydrogen phosphate, Disodium phosphate dehydrate, Potassium chloride, Egg protein, Calcium chloride, Magnesium chloride hexahydrate, Virus: Influenza.
Product Descriptions

Package Insert



Mastaflu influenza vaccine, surface antigen, inactivated
Manufacturer Solvay
Microorganism Influenza
Licensed
Recommendations adults and children from 36 months, single dose
Ingredients Sodium chloride, Potassium dihydrogen phosphate, Disodium phosphate dehydrate, Potassium chloride, Egg protein, Calcium chloride, Magnesium chloride hexahydrate, Virus: Influenza.
Product Descriptions

http://emc.medicines.org.uk/eMC/assets/c/html/DisplayDoc.asp?DocumentID=12737

Mutagrip Influenza Vaccine (SPLIT VIRION)
Manufacturer Aventis
Microorganism Influenza
Licensed 08/28/1998
Recommendations Single 0.5 mL i.m. injection for those 36 months of age and older.
Ingredients Sodium chloride, Disodium phosphate dehydrate, Potassium chloride, Monopotassium phosphate, Egg protein, Virus: Influenza.
Product Descriptions

http://home.intekom.com/pharm/ranbaxy/mutagrip.html
German:
http://www.impfkritik.de/fachinfo/influenza-mutagrip-aventis-2004-2005.pdf
http://www.pei.de/nn_163516/EN/drugs/impfstoffe-am-en/influenza-en/influenza-node-en.html?__nnn=true

Optaflu
Manufacturer Novartis
Microorganism Influenza (flu) virus
Licensed June 13, 2007 (EU)
Recommendations One intramuscular injection, seasonally
Ingredients Dog kidney cells.
Product Descriptions

Dr. Sherri Tenpenny Speaks Out
"The Hidden Hazards of the New Flu Vaccine, OptaFlu"



Pandemrix (swine flu) Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)
Manufacturer GlaxoSmithKline
Microorganism A/California/7/2009 (H1N1)v-like strain (X-179A)
Licensed 20/05/2008 (EU/1/08/452/001)
Recommendations Adults aged 18-60 years: One dose of 0.5 ml at an elected date. A second dose of vaccine should preferably be given. There should be an interval of at least threeweeks between the first and second dose. However, preliminary immunogenicity data obtained at three weeks after administration of an investigational formulation of Pandemrix (H1N1) to a limited number of healthy adults aged 18-60 years suggest that a single dose may be sufficient in this age group. See section 5.1. Elderly (>60 years) --One dose of 0.5 ml at an elected date. A second dose of vaccine should be given after an interval of at least three weeks. See section 5.1. Children and adolescents aged 10-17 years -- If vaccination is considered to be necessary, consideration may be given to dosing in accordance with the recommendations for adults. However, the choice of dose for this age group should take into account the available data on safety and immunogenicity in adults and in children aged from 3-9 years. Children aged 3-9 years -- If vaccination is considered to be necessary, the available data suggest that administration of 0.25 ml of vaccine (i.e. half of the adult dose) at an elected date and a second dose administered at least three weeks later may be sufficient. There are very limited safety and immunogenicity data available on the administration of AS03- adjuvanted vaccine containing 3.75 ìg HA derived from A/Vietnam/1194/2004 (H5N1) and on administration of half a dose of the same vaccine (i.e. 1.875 ìg HA and half the amount of AS03 adjuvant in 0.25 ml ) at 0 and 21 days in this age group. Children aged from 6 months to 3 years -- If vaccination is considered to be necessary, consideration may be given to dosing in accordance with the recommendation in children aged 3-9 years. Children aged less than 6 months -- Vaccination is not currently recommended in this age group.
Ingredients Formaldehyde, Gentamicin Sulfate, Polysorbate 80, Squalene, Thimerosal, Mercury, Sodium chloride, Ovalbumin (egg), Potassium dihydrogen phosphate, Potassium chloride, Egg protein, Magnesium chloride hexahydrate, Octoxynol-10 (or 9), Sodium deoxycholate, AS03 , DL-á-tocopherol, Disodium hydrogen phosphate .
Product Descriptions

Package Insert (GSK manufacturer)

Vaxigrip Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)
Manufacturer Sanofi Pasteur
Microorganism Influenza
Licensed
Recommendations 6 months of age or older
Ingredients Formaldehyde, Neomycin, Sucrose, Thimerosal, Sodium phosphate, Virus: Influenza, Triton X-100.
Product Descriptions

Package Insert




  WAVE - Common Menu
Navigate
Learn About
  Specific Vaccines
  Reactions / Conditions
  Vaccine Risks
  Vaccine Ineffectiveness
  Vaccine Ingredients
  How? Why?
  Authorities Speak Out
  Law / Exemptions

Communicate
  Vaccine Blog
  Discussion Forum
  Receive Newsletter
  Send to a Friend

Contribute
  Take a Stand
  Add to the Database
  Testimonials
  Link to WAVE
  Donate

Recommended
  Products
  Web Sites
  Seminars
  News and Views